Skip to content

TAC accuses South African govt of back pedalling on treatment promise

Studies provide more information on HIV, HAART and heart disease

Tenofovir approved for first-line therapy in European Union

More scepticism than enthusiasm for VaxGen claims on race and AIDS vaccine response

US study finds poor adherence, depression, drug use and unprotected sex linked

Nevirapine studied as pre-exposure prophylaxis for HIV: safe in 200 mg dose

Tipranavir shows activity for PI-resistant patients

VaxGen pledges continued efforts for an AIDS vaccine

HIV vaccine fails in first large trial; may protect Blacks, Asians only